Table 9. Sensitivity analysis for chronic disease reversal following MDA.
| Selected Studies | Hydrocele Reversal/ Improvement | Hydrocele Patients (n) | Lymphedema Reversal/ Improvement | Lymphedema Patients (n) | Estimated Economic Benefit Based on Study Parameters (US$MM) | Avg, % of Annual Lost Income (Work Days) Prevented |
| Ciferri 1960, Dunyo 2000, Das 20031 | 0% | 37 | 0% | 26–48 | $18,890 | 5.5% |
| Partono 1985 | - | - | 71% | 49 | $27,590 | 8.0% |
| Partono 1981 | - | - | 75% | 20 | $28,010 | 8.1% |
| Mackenzie 2009 | 15% | 13 | 98% | 62 | $31,020 | 9.0% |
| Meyrowitsch 1996 | 67% | 60 | 39% | 26 | $31,700 | 9.2% |
| Bockarie 2002 | 87% | 105 | 69% | 90 | $37,390 | 11.0% |
| Base model estimates | 10% | - | 15% | - | $21,815 | 6.3% |
1
No change or results considered insignificant.